Jazz Pharmaceuticals misses top-line and bottom-line estimates; reaffirms FY24 outlook

seekingalpha05-02

Jazz Pharmaceuticals press release (NASDAQ:JAZZ): Q1 Non-GAAP EPS of $2.68 misses by $1.50. Revenue of $901.98M (+1.0% Y/Y) misses by $52.34M. As of March 31, 2024, cash, cash equivalents and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2432375276?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-02 04:23","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2432375276","market":"sh","top_or_hot":-1,"title":"Jazz Pharmaceuticals misses top-line and bottom-line estimates; reaffirms FY24 outlook","media":"seekingalpha","content":"<div>\n<p>Jazz Pharmaceuticals press release (NASDAQ:JAZZ): Q1 Non-GAAP EPS of $2.68  misses by $1.50. Revenue of $901.98M (+1.0% Y/Y)  misses by $52.34M. As of March 31, 2024, cash, cash equivalents and ...</p>\n\n<a href=\"https://seekingalpha.com/news/4097893-jazz-pharmaceuticals-misses-top-line-and-bottom-line-estimates-reaffirms-fy24-outlook\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jazz Pharmaceuticals misses top-line and bottom-line estimates; reaffirms FY24 outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJazz Pharmaceuticals misses top-line and bottom-line estimates; reaffirms FY24 outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-02 04:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4097893-jazz-pharmaceuticals-misses-top-line-and-bottom-line-estimates-reaffirms-fy24-outlook><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Jazz Pharmaceuticals press release (NASDAQ:JAZZ): Q1 Non-GAAP EPS of $2.68  misses by $1.50. Revenue of $901.98M (+1.0% Y/Y)  misses by $52.34M. As of March 31, 2024, cash, cash equivalents and ...</p>\n\n<a href=\"https://seekingalpha.com/news/4097893-jazz-pharmaceuticals-misses-top-line-and-bottom-line-estimates-reaffirms-fy24-outlook\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://seekingalpha.com/news/4097893-jazz-pharmaceuticals-misses-top-line-and-bottom-line-estimates-reaffirms-fy24-outlook","article_id":"2432375276","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2432375276","pubTimestamp":1714595024,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Jazz Pharmaceuticals press release : Q1 Non-GAAP EPS of $2.68  misses by $1.50. Revenue of $901.98M   misses by $52.34M. As of March 31, 2024, cash, cash equivalents and investments were $1.8 billion, and the outstanding principal balance of the Company's long-term debt was $5.8 billion.  Outlook: 2024 total revenue guidance affirmed at $4.0 to $4.2 billion  The Company is affirming its full year 2024 financial guidance as follows:        Guidance   Revenues     $4,000 - $4,200 vs. $4.09B consensus   –Neuroscience      $2,800 - $2,950   –Oncology     $1,120 - $1,220      GAAP   Non-GAAP   Gross margin % 89 %   93%    SG&A expenses $1,346 - $1,426   $1,170 - $1,230    SG&A expenses as % of total revenues 32% - 36%   28% - 31%   R&D expenses $877 - $935   $800 - $850    R&D expenses as % of total revenues 21% - 23%   19% - 21%   Effective tax rate % - %   10% - 13%    Net income $385 - $530   $1,275 - $1,350    Net income per diluted share  $5.80 - $7.70   $18.15 - $19.3  vs. $18.95 cons","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","JAZZ":"爵士制药"},"translate_title":"Jazz Pharmaceuticals没有达到顶线和底线估计；重申2014财年展望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAZZ":1},"content_text":"Jazz Pharmaceuticals press release (NASDAQ:JAZZ): Q1 Non-GAAP EPS of $2.68  misses by $1.50. Revenue of $901.98M (+1.0% Y/Y)  misses by $52.34M. As of March 31, 2024, cash, cash equivalents and investments were $1.8 billion, and the outstanding principal balance of the Company's long-term debt was $5.8 billion.  Outlook: 2024 total revenue guidance affirmed at $4.0 to $4.2 billion  The Company is affirming its full year 2024 financial guidance as follows:   (In millions)     Guidance   Revenues     $4,000 - $4,200 vs. $4.09B consensus   –Neuroscience (includes royalties from high-sodium oxybate AG)     $2,800 - $2,950   –Oncology     $1,120 - $1,220     (In millions, except per share amounts and percentages) GAAP   Non-GAAP   Gross margin % 89 %   93%    SG&A expenses $1,346 - $1,426   $1,170 - $1,230    SG&A expenses as % of total revenues 32% - 36%   28% - 31%   R&D expenses $877 - $935   $800 - $850    R&D expenses as % of total revenues 21% - 23%   19% - 21%   Effective tax rate (22)% - (3)%   10% - 13%    Net income $385 - $530   $1,275 - $1,350    Net income per diluted share  $5.80 - $7.70   $18.15 - $19.3  vs. $18.95 consensus","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2432375276"}